EntreMed Announces 2008 Corporate and Clinical Program ...( ROCKVILLE Md. March 13 /- EntreMe...)

ROCKVILLE, Md., March 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced its 2008 corporate and clinical program priorities. Formal remarks regarding corporate objectives, as well as plans for current and future clinical development milestones were delivered this morning by EntreMed President and CEO, James S. Burns, during the Company's year-end 2007 update call.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

EntreMed reiterated its strategy of investing behind multiple clinical- stage oncology product candidates. In 2008, EntreMed plans to focus in three principal objectives.

-- Concentrate resources on fewer programs that provide a more direct path

forward to product registration and ultimately to the market;

-- Conserve cash by funding essential priority program activities and

deferring new program initiatives; and

-- Expand partnering activities across multiple clinical programs.

EntreMed also announced that the Company has reprioritized its development pipeline to focus investment on three of its oncology programs, specifically: MKC-1, ENMD-1198, and ENMD-2076.

-- MKC-1 is a novel, orally-active cell cycle inhibitor with broad-acting

antitumor activity, including tumor growth inhibition or regression in

multiple preclinical models. MKC-1 has been shown to inhibit the PI3K

Akt-mTOR signaling pathway, which occurs through inhibition of the

mTOR/rictor branch of the pathway. MKC-1 was
'/>"/>